Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
SEC vs Ripple: Allegations of XRP Price Manipulation Surface

SEC vs Ripple: Allegations of XRP Price Manipulation Surface

DailyCoinDailyCoin2024/03/01 22:40
By:DailyCoin
  • Court documents have revealed a potential collaboration between Ripple and a market maker to influence XRP’s price.
  • Some experts have claimed manipulation, and others have suggested it was part of stabilization efforts.
  • These developments have added another layer to the ongoing legal battle between Ripple and the SEC.

Court documents surfacing in the ongoing SEC vs Ripple lawsuit have ignited a firestorm of debate within the cryptocurrency community. These documents raise questions about the potential manipulation of the XRP price by Ripple , adding a new layer of complexity to the already intricate legal battle.

Did Ripple Use Bots to Manipulate XRP?

The claims stem from revelations shared by crypto researcher Darkhorse, who unearthed documents detailing interactions between Ripple and market maker GSR Markets. These documents allegedly outline strategies employed by Ripple to influence XRP’s market value during 2015 and 2016.

Specifically, the documents mention “xrp 2t 6t bots” and suggest that GSR was instructed to buy and sell XRP to impact its price. Notably, the documents reportedly link these actions to bots operated by high-profile figures within Ripple, including CEO Brad Garlinghouse and co-founder Chris Larsen .

Further bolstering these claims, screenshots shared by Darkhorse depict a graph indicating a seemingly direct correlation between GSR’s net XRP sales and XRP/USD price movements. This graph, sourced from GSR’s records, reportedly shows strategic pauses in selling during price dips, followed by resumed sales upon receiving specific signals from Ripple.

🫡🫡🫡 For all those who want to know how the xrp 2t 6t bots were used and GSR was employed to sell and buy and the effects on the price, I finally found the document that explains it all. Including Brad and Chrises bots.
Apologies for the delay. https://t.co/DIEsbtn6Jq pic.twitter.com/kj4WRvbnX8

— ĐΛRKHØRSΞ™ (@DarkhorseDNME4) February 28, 2024

Darkhorse elaborates on the alleged tactics, suggesting a pattern of “buying to create a price rally” and then “selling into the rally” to capitalize on FOMO among investors. However, respected XRP community member Wrathof Kahneman emphasizes that the documents might describe efforts to stabilize and boost, rather than suppress, the price.

Delays and Transparency Concerns Impact XRP

Ripple has yet to address these specific allegations publicly.  This situation raises concerns about transparency and fairness in the XRP market, potentially impacting investor trust. It adds another layer of complexity to the ongoing SEC lawsuit, which is already facing delays.

The SEC recently requested an extension for submitting briefs related to the remedies phase of the lawsuit, pushing back deadlines for both parties. This development further highlights the intricate and evolving nature of this legal battle with significant implications for the future of XRP.

On the Flipside

  • The actions described could be interpreted as market-making activities to increase liquidity, a common practice in traditional finance.
  • The interpretation of the documents and graphs by Darkhorse is one perspective, and others, like Wrathof Kahneman, offer alternative explanations.
  • The authenticity and credibility of Darkhorse’s research and interpretation of the documents require further verification.

Why This Matters

If proven true, these accusations could erode investor confidence in XRP and the broader crypto market by raising concerns about manipulation and unfair advantage. The legal battle’s outcome could set a precedent for how regulators approach similar situations in the future.

To learn more about how XRPL and Axelar are aiming to connect blockchain ecosystems, read here:
How XRPL and Axelar Aim to Connect Blockchain Ecosystems

To learn more about why XRP is struggling to keep up with the market despite a 65% volume surge, read here:
XRP Struggles to Keep Up with Market Despite 65% Volume Surge

2
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Wall Street Stands Guard as Bessent Strikes Again: Aftereffects of August's "Treasury Turnaround" Persist, November Refinancing Notice Could Be the Next Flashpoint

As the US Treasury prepares to update its debt management plan in November, key clues may emerge on Friday.

智通财经•2026/10/16 01:06

"Coca-Cola belief" never goes out of style! KFC in America says goodbye to Pepsi and embraces Coca-Cola (KO.US); Buffett-style "boring investment" returns to the spotlight

KFC has chosen Coca-Cola as its soda supplier in the United States, abandoning its long-term partner Pepsi. As of the close of the U.S. stock market on Thursday, Coca-Cola's (KO.US) stock price reached a record high, defying the ongoing declines in global tech stocks, especially in the semiconductor and broad AI computing sectors.

智通财经•2026/10/16 01:06

AI financing concerns weigh heavily on chip stocks, global tech sector has lost over $1 trillion this week

Multiple pressures, including rising expectations of a Federal Reserve rate hike and increasing AI financing costs, have led to a massive sell-off in global tech stocks this week. The combined market value of the world's top 20 AI and semiconductor stocks has evaporated by more than $1 trillion, and the semiconductor ETF (SOXX) has recorded its longest losing streak in 11 years. On Thursday, SK Hynix continued to plunge by over 10% in a single day, while Nvidia, Samsung, and SoftBank were not spared.

华尔街见闻•2026/10/16 00:51

Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs

Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.

华尔街见闻•2026/10/16 00:37
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs